Literature DB >> 19229883

Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells.

Jian Xiao1, Zheng-Jun Xiao, Zhen-Guo Liu, Huan-Yu Gong, Qiong Yuan, Shan Wang, Yuan-Jian Li, De-Jian Jiang.   

Abstract

BACKGROUND: Visfatin, a new adipocytokine, was reported to promote angiogenesis. Dimethylarginine dimethylaminohydrolase (DDAH), which could regulate vascular endothelial growth factor (VEGF) expression in endothelial cells, is thought as a novel modulator of angiogenesis. The aim of the study was to investigate the role of DDAH2 in visfatin-induced angiogenesis in human umbilical vein endothelial cells (HUVECs). METHODS AND
RESULTS: Visfatin could concentration- and time-dependently enhance cell migration and tube formation reflecting angiogenic capability of HUVECs. Moreover, visfatin upregulated both mRNA and protein expressions of DDAH2 and VEGF. Angiogenic effects of visfatin were attenuated by DDAH2 small interfering RNA. Visfatin-induced protein kinase B (Akt) phosphorylation and phosphoinositide 3 kinase (PI3K) inhibitors could suppress visfatin-induced upregulation of DDAH2 and VEGF expressions.
CONCLUSIONS: Taken together, our results demonstrate that PI3K/Akt-mediated upregulation of DDAH2 expression plays a critical role in visfatin-promoted angiogenesis via regulating VEGF-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229883     DOI: 10.1002/dmrr.939

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  12 in total

1.  Protective effect of HDL on endothelial NO production: the role of DDAH/ADMA pathway.

Authors:  Zhen-Yu Peng; Shui-Ping Zhao; Bai-Mei He; Dao-Quan Peng; Min Hu
Journal:  Mol Cell Biochem       Date:  2011-01-25       Impact factor: 3.396

2.  Severe degenerative aortic stenosis with preserved ejection fraction does not change adipokines serum levels.

Authors:  Katarzyna Mizia-Stec; Tomasz Bochenek; Błażej Kusz; Magdalena Mizia-Szubryt; Agnieszka Sikora-Puz; Klaudia Gieszczyk-Strózik
Journal:  Cardiol J       Date:  2017-11-23       Impact factor: 2.737

3.  Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent manner.

Authors:  Radu C Oita; Dudley Ferdinando; Steve Wilson; Christopher Bunce; Dawn J Mazzatti
Journal:  Pflugers Arch       Date:  2009-11-08       Impact factor: 3.657

4.  Visfatin/PBEF/Nampt: A New Cardiovascular Target?

Authors:  Concepción Peiró; Tania Romacho; Raffaele Carraro; Carlos F Sánchez-Ferrer
Journal:  Front Pharmacol       Date:  2010-11-23       Impact factor: 5.810

5.  Serum and vitreous levels of visfatin in patients with diabetic retinopathy.

Authors:  Yongqiang Wang; Ye Yuan; Hua Jiang
Journal:  Med Sci Monit       Date:  2014-12-19

6.  Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.

Authors:  Toshihiro Shiozawa; Shinji Iyama; Shotaro Toshima; Akiko Sakata; Shingo Usui; Yuko Minami; Yukio Sato; Nobuyuki Hizawa; Masayuki Noguchi
Journal:  Virchows Arch       Date:  2015-10-29       Impact factor: 4.064

7.  Visfatin Promotes Wound Healing through the Activation of ERK1/2 and JNK1/2 Pathway.

Authors:  Byung-Cheol Lee; Jisun Song; Arim Lee; Daeho Cho; Tae Sung Kim
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

Review 8.  Visfatin/Nampt: an adipokine with cardiovascular impact.

Authors:  Tania Romacho; Carlos F Sánchez-Ferrer; Concepción Peiró
Journal:  Mediators Inflamm       Date:  2013-06-16       Impact factor: 4.711

Review 9.  The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.

Authors:  Larisa Diana Mocan Hognogi; Luminita Vida Simiti
Journal:  Clujul Med       Date:  2016-07-28

10.  Hyperbaric oxygen activates visfatin expression and angiogenesis via angiotensin II and JNK pathway in hypoxic human coronary artery endothelial cells.

Authors:  Chiung-Zuan Chiu; Bao-Wei Wang; Ying-Ju Yu; Kou-Gi Shyu
Journal:  J Cell Mol Med       Date:  2020-01-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.